Richard Daly

Chief Operating Officer at Seed Therapeutics

Mr. Daly joins the company with more than 25 years of experience leading business and commercial operations for major pharmaceutical and biotech companies, including Executive Vice President at Takeda Pharmaceuticals U.S.A., Inc. and as President of AstraZeneca’s U.S. Diabetes subsidiary. Most recently, Mr. Daly served as CEO, President, and Chairman of Neuralstem, Inc. Mr. Daly currently serves on the boards of Catalyst Pharmaceuticals and Opiant Pharmaceuticals.

Mr. Daly was instrumental in building Takeda North America from 14 people to more than 3,000 employees and $5 billion in sales in less than seven years. During his 13-year tenure, he served as Executive Vice President for the U.S., where he was responsible for business development for the Americas and expanding the company’s commercial footprint across North and South America and into new therapeutic areas, including oncology. As President of AstraZeneca’s U.S. Diabetes subsidiary, Mr. Daly led commercial initiatives that transformed the Bristol-Myers Squibb and AstraZeneca Diabetes Alliance into the fastest-growing diabetes franchise in the U.S. in less than 12 months.

Mr. Daly earned an M.B.A. from Northwestern University’s Kellogg School of Management and holds a B.S. in microbiology from the University of Notre Dame.

Timeline

  • Chief Operating Officer

    Current role